Last reviewed · How we verify

NCT05403840: STRESS-MR

Haemodynamics of Mitral Regurgitation Reduction

Status unknown Last updated 3 June 2022
What this trial tests

trial testing Mitral valve surgery in Mitral Regurgitation in 60 participants. Status unknown.

Timeline
6 June 2022
Primary endpoint
6 June 2024
6 January 2025

Quick facts

Lead sponsorGuy's and St Thomas' NHS Foundation Trust
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment60
Start date6 June 2022
Primary completion6 June 2024
Estimated completion6 January 2025

Drugs / interventions tested

Conditions studied

Sponsor

Guy's and St Thomas' NHS Foundation Trust

Who can join

18 and older, any sex, with Mitral Regurgitation. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

There is uncertainty in terms of the superiority of conventional valve surgery or percutaneous transcatheter intervention for the treatment of severe mitral regurgitation (MR) in high risk patients. The post procedural haemodynamics of the different treatment options in those at high surgical risk is poorly understood. This study seeks to characterise the physiological changes and functional outcomes of patients undergoing either surgery or transcatheter intervention.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Mitral valve surgery

Trials testing the same drug.

Other recruiting trials for Mitral Regurgitation

Currently open trials in the same condition.

Other Guy's and St Thomas' NHS Foundation Trust trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05403840.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing